Novo Holdings is a holding company specializing in life science investors with a focus on creating long-term value.

Novo Holdings

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

MPM Capital

[Mitsui & Co. Global Investment](http://www.mitsui-global.com/en/) is a venture capital fund that focuses on early stage companies.  Mitsui's expertise lies in helping companies build their business globally.  Mitsui & Co. Global Investment Co. is an investment company as a division of the financial business, to invest in companies that significant growth is expected. The headquarters in Tokyo, and we are investing activities from a global perspective, as opposed to complete in each country and a network of offices in Silicon Valley, Beijing, Mumbai, while also focusing on Japan and the United States China and India.

Mitsui Global Investment

Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies.

Arkin Bio Ventures

FemHealth Ventures invests in groundbreaking innovators in women’s health, focusing on drugs, devices, diagnostics, and digital applications. We are (re)imagining women’s health to include conditions that affect only women, affect mostly women, or appear differently in women.

FemHealth Ventures

The future of mental wellness is being built today. Through its diversified investment fund, Palo Santo is positioned to increase the supply of clinically effective, affordable, and accessible mental health and addiction treatment solutions needed in today’s world. Supported by a rapidly growing body of evidence and strong FDA support, psychedelic-assisted treatments represent a paradigm shift in mental health care. Yet the emerging ecosystem of business opportunities is highly fragmented and, with a lack of institutional capital available, Palo Santo is targeting high growth opportunities within biotech & drug development, health care services, and digital health solutions led by passionate, experienced, and ethical management teams. These businesses are positioned to have a profound impact on treating conditions such as depression, PTSD, anxiety, OCD, drug and alcohol dependence, chronic pain, Alzheimer’s, and a range of inflammatory-related illnesses.

Palo Santo Fund

Plaisance Capital Management  identifies and invests in biotechnology startups.

Plaisance Capital Management

Reunion Neuroscience

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Toronto-based Reunion Neuroscience (formerly Field Trip Health) is a mental wellness company developing and delivering psychedelic therapies to treat mental disorders such as depression, post-traumatic stress disorder (PTSD), and anxiety.&nbsp;

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

Seleni Institute

To sponsor maternal mental health training courses which aligns with Reunion's ongoing Phase II RECONNECT trial, which evaluates RE104 for treating postpartum depression.

Companies conducting research on psychedelic compounds and developing novel therapeutics.

Toronto-based Reunion Neuroscience (formerly Field Trip Health) is a mental wellness company developing and delivering psychedelic therapies to treat mental disorders such as depression, post-traumatic stress disorder (PTSD), and anxiety.&nbsp;Reunion was formed after Field Trip Health (FTH) split its business into two separate entities in <a href="https://sp-edge.com/updates/12323">August 2022 </a>. FTH’s Discovery division, which focused on research and development was rebranded as Reunion Neuroscience Inc whilst the Health Division, focusing on clinics, was renamed as Field Trip Health and Wellness (FTHW). Post the restructuring, Reunion was set to hold 21.84% of the shares in FTHW.Reunion conducts research at the University of West Indies in Jamaica, and was developing RE104 (formerly FT-104), its first drug candidate that is similar to psilocybin in potency. In July 2022, the first dosing of the candidate in the Phase I clinical stage in Australia, was completed, with the results having been expected to be released by the end of CY2022. A Phase II was also slated for 2023. Reunion is also working on a new pipeline research program (FT-200) to discover novel psychedelics for cardiovascular risks.&nbsp;From <a href="https://sp-edge.com/updates/17104">April 2023 </a>onwards, FTHW operated 7 clinics across North America and Europe. These clinics support ketamine-assisted therapies, with plans to add other substances, including psilocybin, once permitted. In August 2020, Field Trip launched its free digital app which provides a framework and tools to support meditation and breathwork. The company also had a digital portal that provided users with information and tools related to psychedelic therapies to enhance and optimize the therapeutic experience provided via its clinics.&nbsp;FTHW’s primary strategy is to use the clinic model for immediate revenue generation while also making them an integral part of the company’s R&amp;D structure.&nbsp;In <a href="https://sp-edge.com/updates/19274">June 2023 </a>, the company went private through a USD 13.1 million deal with MPM BioImpact.&nbsp;Key customers and partnershipsIn <a href="https://sp-edge.com/updates/28499">April 2024 </a>, the company partnered with Fluence to conduct a Phase II clinical trial of RE104. Further in&nbsp;<a href="https://sp-edge.com/updates/34672">October 2024</a>, the company partnered with Seleni Institute, a nonprofit organization, to sponsor maternal mental health training courses.

<div>
 
 Canadian biotech firm Core One Labs maintains three primary business operations: 1) developing novel delivery systems for psychedelic medicines, 2) psilocybin manufacturing, and 3) medical clinics to provide psychedelic-assisted psychotherapy. The company has developed proprietary technology with infused strips that dissolve immediately when placed in the patient&rsquo;s mouth to deliver molecules with a higher level of bioavailability. The company plans to advance this technology to incorporate psychedelic molecules, particularly psilocybin.&nbsp;
 
 
 Core One Labs also claims it has discovered a patentable method of producing high-quality psilocybin, which it may license to pharmaceutical companies. Additionally, the company has two psychedelic clinics in Vancouver that currently support clinical trials and maintain a database of more than 275,000 patients. The company acquired Vocan Biotechnologies and Akome Biotech in May 2021 for undisclosed amounts. Akome is developing a patent-pending psychedelic drug formulation for the treatment of Alzheimer&rsquo;s Disease.&nbsp;
 
 
 Core One Labs is listed on the Canadian Securities Exchange (CSE) and OTC markets.
 
 
</div>

Core One Labs

<div>
 
 Vancouver-based Lobe Sciences (formerly GreenStar Biosciences) is a biotechnology company developing psychedelic medicines (microdose applications) and medical devices for efficient drug delivery. The company&rsquo;s main focus is the treatment of mild traumatic brain injury and post-traumatic stress disorder (PTSD). It is also conducting early studies on psilocybin combined with N-acetylcysteine (NAC), and MDMA combined with NAC as a treatment. Lobe is also developing a patent pending nasal mist transducer device for the delivery of medicines directly to the brain&rsquo;s olfactory bulb.&nbsp;
 
 
 In June 2020, Lobe acquired Eleusian Biosciences, a company focused on the development of psychedelic medicine which expanded its intellectual property portfolio with three US patent applications for psychedelic therapeutics. Lobe is also collaborating with the University of Miami&rsquo;s Miller School of Medicine to conduct preclinical studies. After its restructuring and name change, the company started trading on the Canadian Securities Exchange (CSE) in November 2020.
 
 
 
</div>

Lobe Sciences

<div>
 
 Cybin is a psychedelic biotechnology company developing treatments for psychiatric and neurological conditions. Through its Serenity Life Science division, Cybin conducted Phase II of clinical trials on using psilocybin to treat major depressive disorder. Additionally, the company's Nature's Journey division focuses on creating non-psychedelic medicinal and nutraceutical mental health products.
 
 
 Cybin is actively building a patent portfolio, including chemically-synthesized compounds, delivery mechanisms, protocols, and new drug formulations. It has also filed an International Patent Application through the Patent Cooperation Treaty, potentially covering 153 countries.&nbsp;
 
 
 In July 2023, the company announced 
 <a href="https://sp-edge.com/updates/20076">
 EMBARKCT, 
 </a>
 a streamlined version of its EMBARK training program for pivotal studies of lead candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, respectively. In 
 <a href="https://sp-edge.com/updates/27577">
 March 2024
 </a>
 , the company received a breakthrough designation from the FDA for CYB003, and expects to initiate Phase III clinical trials for the program by mid-2024.
 
 
 Cybin implements an M&amp;A strategy to grow in the psychedelic industry. It did a reverse takeover of Charmin in June 2020, raising CAD 45 million (USD 35.5 million) for clinical studies. It acquired Adelia Therapeutics in December 2020, adding novel treatments and patent applications. Also in 
 <a href="https://sp-edge.com/updates/21335">
 August 2023 
 </a>
 it acquired 
 <a href="https://sp-edge.com/companies/470858">
 Small Pharma 
 </a>
 in an all-share transaction to strengthen its psychedelic portfolio.&nbsp;
 
 
 Founded in 2019, Cybin is listed on the NEO exchange under the ticker symbol &ldquo;CYBN&rdquo; and was uplisted to the NYSE American Stock Exchange in July 2021 under the same symbol. For FY2023, the company reported a decrease in net loss by 29.7% YoY to CAD 47.5 million (USD 35 million).&nbsp;
 Further in 
 <a href="https://sp-edge.com/updates/33849">
 September 2024
 </a>
 , it completed a 38-to-1 share consolidation of its common stock which reduced the number of outstanding common shares to ~20 million. 
 
 
 Key customers and partnerships&nbsp;
 
 
 In July 2020, Cybin expanded its operations and research activities in the European region via research partnerships and transferred its intellectual property assets to its fully-owned Irish subsidiary (formed in May 2021). In July 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/20455">
 Worldwide Clinical Trials
 </a>
 to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder. Further, in September 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/22180">
 Fluence
 </a>
 to support Cybin's EMBARK facilitator training program.
 
</div>

Cybin

<div>
 
 Canadian cannabinoid-based therapeutics company BioNxt Solutions
 (formerly Xphyto Therapeutics) announced in November 2020 that it has expanded its drug development program to incorporate a number of psychedelic compounds. This includes substances such as psilocybin, mescaline, LSD, MDMA, and DMT. Xphyto&rsquo;s initial focus is on developing standardized drug formulations with efficient delivery mechanisms for therapeutic use.
 
</div>

BioNxt Solutions

<div>
 
 New York-based Gilgamesh Pharmaceuticals is a biotechnology company developing psychedelic-inspired medicines for neuropsychiatric conditions such as depression, anxiety, addiction, and cognitive deficits. The company has three research programs in its pipeline: 1) Serotonergic Micro-Dose&ndash;a non psychedelic therapeutic treatment for attention deficit hyperactivity disorder (ADHD) and mood/anxiety disorders, 2) Arylcyclohexylamine&ndash;an improved molecule of ketamine for treatment-resistant depression and opiate use disorder, and 3) Novel Ibogaine Analogue&ndash;for the treatment of substance use disorders.&nbsp;
 
 
 Gilgamesh is one of the few psychedelic companies launched by the startup accelerator Y Combinator, and as such enjoys the accelerator&rsquo;s world-famous business expertise and network.
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/29382">
 May 2024
 </a>
 , the company partnered with AbbVie to leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel &quot;neuroplastogens.&quot; 
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27575">
 March 2024
 </a>
 , the company received a grant of&nbsp; USD 14 million from the National Institute on Drug Abuse to develop the GM-3009 compound. Prior to this, it raised USD 39 million in a 
 <a href="https://sp-edge.com/updates/15359">
 Series B 
 </a>
 funding round led by Prime Movers Lab in December 2022. 
 
</div>

Gilgamesh Pharmaceuticals

Companies operating digital platforms to deliver psychedelic therapies including psychedelic integration, virtual experiences, and mental coaching and tracking. AI drug discovery companies specializing in psychedelic therapeutics are also included.

Companies operating clinics and treatment centers to deliver psychedelic therapies.

Companies supplying psychedelic compounds through cultivation, chemical synthesis and biosynthesis for medical research and drug development.

Companies building a patent portfolio of novel analogs and derivatives of first-generation psychedelics and new drug delivery mechanisms. 

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 
 Reunion Neuroscience, a psychedelic therapy company based in Toronto, has formed a partnership with the Seleni Institute, a nonprofit organization. The aim of this partnership is to sponsor training courses focused on maternal mental health.
 The goal of this collaboration is to grant healthcare professionals access to evidence-based maternal mental health training offered by the Seleni Institute. The training covers maternal mental health conditions such as perinatal mood and anxiety disorders, and postpartum depression. Through their sponsorship, Reunion aims to improve both the diagnosis and treatment of these maternal mental health disorders.
 
</div> Analyst QuickTake: 
 This partnership aligns with Reunion's ongoing Phase II RECONNECT trial, which evaluates RE104 for treating postpartum depression. In <a href="https: 
//sp-edge.com/updates/28499"> April 2024 </a> , the company also partnered with Fluence to receive psychedelic training support for its Phase II clinical trial.

Reunion Neuroscience

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless